Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management
Source: OncLive, February 2024
Afreen Shariff, MD, MBBS, examines the surveillance and management of immunotherapy-induced adrenal insufficiency in the context of melanoma, underscoring the importance of maintaining a heightened awareness for early detection.
This is a video synopsis/summary of an OncLive Insights® involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.
Khushalani notes increased use of various immunotherapy combinations for metastatic or neoadjuvant melanoma, raising concerns for subtle adrenal insufficiency, which is still common. Shariff highlights the importance of maintaining a high suspicion based on subjective fatigue severity/progression and objective trends in weight, blood pressure, and electrolyte level to determine whether laboratory tests are needed. Recognizing adrenal crisis signs preoperatively also matters.